Fusion neoantigens for use in cancer vaccines, antibody therapy, and cell therapies

A composition comprising:

• a) at least a portion of at least one fusion neoantigen selected from:
• i) an EWSR1-FLi1 fusion protein, ii) an EWS-FEV fusion protein;
• iii) an EWSR1-ERG fusion protein, iv) an EWS-ATF fusion protein;
• v) an EWS-WT1 fusion protein;
• vi) a KMT2A c2318 dupC fusion protein;
• vii) a PAX7-FOXO1 fusion protein;
• viii) a CCNB3-BCOR fusion protein;
• ix) CIC-DVX fusion protein;
• x) SS18-SSX2 fusion protein;
• xi) a FN1fs p.F1778 fusion protein;
• xii) 1 ATRX pD20GG fusion protein;
• and xiii) frameshift 2:2FHX3 p.F297 fusion protein,
• wherein said at least one fusion neoantigen is purified and isolated;
• b) a nucleic acid vector comprising a nucleic acid sequence encoding at least a portion of said at least one fusion neoantigen;
• c) an isolated and purified antibody, or antigen-binding fragment of said antibody, the specifically binds at least a portion of said at least one fusion neoantigen;
• d) an antigen presenting cell (APC) that comprises at least a portion of said at least one fusion neoantigen,
• e) a chimeric antigen receptor T-cell (CAR T cell) that expresses a chimeric antigen receptor that is specific for at least a portion of said at least one fusion neoantigen, and/or
• f) an engineered polynucleotide encoding at least a portion of said at least one fusion neoantigen, wherein said engineered polynucleotide is at least partially optimized for enhanced expression, productive co-translational protein folding, increased stability, or a combination thereof.